{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1","upperLimit":"3","value":"3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"}],"units":"Participants"}],"description":"Progression-free survival was defined as the time from date of registration to the date of first documentation of progression or symptomatic deterioration, or death due to any cause. Patients last known to be alive and progression-free were censored at date of last contact.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive E7389 IV on days 1 and 8 of an every 21-day cycle.","id":"OG000","title":"Treatment (E7389 IV)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Every 6 weeks until progression of disease up to a maximum of 3 years after registration.","title":"Progression-Free Survival","type":"SECONDARY","unitOfMeasure":"months"}